Background: Comorbidities are additive diseases and care burdens in urological patients. Determining the epidemiologic profile of comorbidities in urological patients in our setting may help us to better the management of urological disease. Objective: To evaluate the prevalence of comorbidities in urological patients. Patient and Method: We collected comorbidity, urological disease and demographic data in all urological patients managed at the former Military Teaching Hospital of Cotonou from January 1, 2012, to December 31, 2020. We used the software R 4.2.2 to perform descriptive and bi-varied data analysis. Student’s t test was used to compare means. Results: The prevalence of comorbidities was 14.2%, i.e., 601 comorbidity-affected among 4242 patients. The comorbidities predominantly affected men: the sex ratio was 13:1. The presence of comorbidity was correlated with patients’ age (p < 0.001). The comorbidities observed in the 601 affected patients were hypertension (84.5%), diabetes (26.5%), asthma (2%), and heart failure (1.2%). Hypertension (p = 0.001) and asthma (p = 0.030) were correlated with age. No comorbidity was associated with gender. The comorbidities’ prevalence was highest in patients aged 40 - 80 years who presented urological diseases such as BPH (68.9%), Erectile dysfunction (ED) and ejaculatory disorders, overactive bladder (OAB) and neurogenic lower urinary tract dysfunction (LUTD), renal cyst (5%), inguinal hernia (4.2%), urinary stones (2.8%), and prostate cancer (2.3%). Conclusion: The comorbidities’ prevalence was 14.2% in the urological patients. The main comorbidities were hypertension (84.5%) and diabetes mellitus (26.5%).
References
[1]
Froehner, M., Kellner, A.E., Koch, R., et al. (2014) A Combined Index to Classify Prognostic Comorbidity in Candidates for Radical Prostatectomy. BMC Urology, 14, Article No. 28. https://doi.org/10.1186/1471-2490-14-28
[2]
Mayr, R., May, M., Martini, T., Lodde, M., Comploj, E., Pycha, A., Strobel, J., Denzinger, S., Otto, W., Wieland, W., Burger, M. and Fritsche, H.M. (2012) Comorbidity and Performance Indices as Predictors of Cancer-Independent Mortality but Not of Cancer-Specific Mortality after Radical Cystectomy for Urothelial Carcinoma of the Bladder. European Urology, 62, 662-670. https://doi.org/10.1016/j.eururo.2012.03.057
[3]
Charlson, M.E., Carrozzino, D., Guidi, J. and Patierno, C. (2022) Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. Psychiatry and Psychology, 91, 8-35. https://doi.org/10.1159/000521288
[4]
Sossa, J., Fanou, L., Hounto, Y.F., Yevi, D.M.I., Hodonou, F.J.M. and Avakoudjo, D.J.G. (2023) A Panorama of the Urological Diseases at the Former Military Teaching Hospital of Cotonou. Open Journal of Urology, 13, 143-150. https://doi.org/10.4236/oju.2023.135018
[5]
Ofoha, C.G. and Magnus, F.E. (2019) Presentation, Characteristics and Co-Morbidities of Men with Prostate Cancer in Nigeria. Journal of Advances in Medicine and Medical Research, 31, 1-7. https://doi.org/10.9734/jammr/2019/v31i530297
[6]
Kumar, A. and Srivastava, U. (2011) Role of Routine Laboratory Investigations in Preoperative Evaluation. Journal of Anaesthesiology Clinical Pharmacology, 27, 174-179. https://doi.org/10.4103/0970-9185.81824
[7]
Garg, T., Young, A.J., Kost, K.A., Danella, J.F., Larson, S., Nielsen, M.E. and Kirchner, H.L. (2018) Burden of Multiple Chronic Conditions among Patients with Urological Cancer. The Journal of Urology, 199, 543-550. https://doi.org/10.1016/j.juro.2017.08.005
[8]
Guzzo, T.J., Dluzniewski, P., Orosco, R., Platz, E.A., Partin, A.W. and Han, M. (2010) Prediction of Mortality After Radical Prostatectomy by Charlson Comorbidity Index. Urology, 76, 553-557. https://doi.org/10.1016/j.urology.2010.02.069
[9]
Mayr, R., Fritsche, H.M., Pycha, A. and Pycha, A. (2014) Radical Cystectomy and the Implications of Comorbidity. Expert Review of Anticancer Therapy, 14, 289-295. https://doi.org/10.1586/14737140.2014.868775
[10]
Matthes, K.L., Limam, M., Pestoni, G., Held, L., Korol, D. and Rohrmann, S. (2018) Impact of Comorbidities at Diagnosis on Prostate Cancer Treatment and Survival. Journal of Cancer Research and Clinical Oncology, 144, 707-715. https://doi.org/10.1007/s00432-018-2596-6
[11]
Frendl, D.M., FitzGerald, G., Epstein, M.M., Allison, J.J., Sokoloff, M.H. and Ware, J.E. (2020) Predicting the 10-Year Risk of Death from Other Causes in Men with Localized Prostate Cancer Using Patient-Reported Factors: Development of a Tool. PLOS ONE, 15, e0240039. https://doi.org/10.1371/journal.pone.0240039
[12]
Irani, J., Legeais, D., Madec, F.X., Doizi, S., Bensalah, C.K., Mathieu, R., Phé, V., Pignot, G. and Lebacle, C. (2022) Complications chirurgicales en urologie adulte. La prévention [Complications in Urological Surgery. Prevention]. Progrès en Urologie, 32, 919-927. https://doi.org/10.1016/j.purol.2022.08.011
[13]
Demircan, N.C., Alan, Ö., Başoğlu Tüylü, T., Akın Telli T, Arıkan R, Çiçek FC, Ercelep Ö, Öztürk MA, Alsan Çetin İ, Ergelen R, Tinay İ, Akgül Babacan N, Kaya S, Dane F. and Yumuk, P.F. (2020) Impact of the Charlson Comorbidity Index on Dose-Limiting Toxicity and Survival in Locally Advanced and Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib or Pazopanib. Journal of Oncology Pharmacy Practice, 26, 1147-1155. https://doi.org/10.1177/1078155219890032
